Century Therapeutics Inc (IPSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has a cash flow conversion efficiency ratio of -0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.08 Million) by net assets ($158.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Century Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Century Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Century Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Century Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Paiho Ltd
TW:9938
|
0.049x |
|
SHELF DRILLING LTD
F:6SD
|
N/A |
|
PEPPER MONEY LTD.
F:X95
|
N/A |
|
Lindex Group
HE:LINDEX
|
-0.015x |
|
Ocugen Inc
NASDAQ:OCGN
|
-3.754x |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
N/A |
|
Samji Electronics Co. Ltd
KQ:037460
|
-0.371x |
|
Burstone Group Limited
JSE:BTN
|
0.014x |
Annual Cash Flow Conversion Efficiency for Century Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Century Therapeutics Inc (IPSC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $158.94 Million | $-103.88 Million | -0.654x | +4.24% |
| 2024-12-31 | $161.36 Million | $-110.14 Million | -0.683x | -42.73% |
| 2023-12-31 | $184.75 Million | $-88.35 Million | -0.478x | -1130.25% |
| 2022-12-31 | $302.74 Million | $14.05 Million | 0.046x | +120.66% |
| 2021-12-31 | $396.24 Million | $-89.00 Million | -0.225x | -157.92% |
| 2020-12-31 | $-106.41 Million | $-41.27 Million | 0.388x | +120.34% |
| 2019-12-31 | $-91.86 Million | $-16.17 Million | 0.176x | -39.30% |
| 2015-12-31 | $359.71 Million | $104.30 Million | 0.290x | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more